Found 250 Results
Page 6 of 13

Precision of dose and depth delivery with our needle-free jet injections is our highest priority and we have the Quality credentials to prove it.


Precision of dose and depth delivery with our needle-free jet injections is our highest priority and we have the Quality credentials to prove it.At PharmaJet, we are proud to display the framed certificate indicating we are the first and only Needle-free Injection Systems (NFIS) to achieve WHO prequalification (E008/050, E008/071), which is a requirement for...

needle free testing

October 4, 2022


PharmaJet to present latest research showing superior immunogenicity with their Needle-free Systems at Five Conferences in October


GOLDEN, Colo. — September 27, 2022 — PharmaJet®, a company who has developed and commercialized a needle-free platform to more effectively administer drugs and biologics, today announced that their latest research results will be presented at five upcoming conferences in October:

Tags: , , , , , ,

September 23, 2022


PharmaJet presents latest research showing Benefits of Needle-free at Military Health System Research Symposium


GOLDEN, Colo. — September 12, 2022 — PharmaJet®, a company who has developed and commercialized a needle-free platform to more effectively administer drugs and biologics, today announced that they will present their latest research results at the Military Health System Research Symposium (MHSRS) on September 13, 2022. The presentation, entitled Advancement of a Next Generation Needle-Free Injection Device for Effective Delivery of the Venezuelan Equine Encephalitis Virus DNA Vaccine, will be presented by Erin Spiegel, Ph.D., Vice President of Clinical and Regulatory Affairs at PharmaJet. The MHSRS is the foremost scientific meeting for the Department of Defense providing a venue for presenting new scientific knowledge resulting from military-unique research and development.

Tags: , , , , ,

September 7, 2022


WHO selects PharmaJet Needle-free Injection System for Million+ Polio Vaccination Campaign


GOLDEN, Colo. — August 31, 2022 — PharmaJet® , a company who has developed and commercialized an intradermal needle-free platform to more effectively administer drugs and biologics, today announced that the World Health Organization (WHO) selected the PharmaJet Tropis® Needle-free Injection System (NFIS) for large polio vaccination campaigns in Pakistan as part of a broader effort of coordinated campaigns between Pakistan and Afghanistan. Over 2.7 million children have been targeted for this program so far using the PharmaJet Tropis® NFIS.

Tags: ,

August 18, 2022


University of Adelaide begins Human Trial of Omicron COVID vaccine booster using PharmaJet Needle-free System


GOLDEN, Colo. — August 16, 2022 — PharmaJet® , a company that has developed and commercialized a needle-free platform to more effectively administer drugs and biologics announced that its partner, University of Adelaide, has started a human trial of a DNA-based COVID-19 vaccine booster using the PharmaJet Tropis® Needle-free Injection System (NFIS).

Tags: , , ,

August 3, 2022


PharmaJet Partner, Scancell, Announces Phase 2 Melanoma DNA Vaccine Trial will include Needle-free Delivery


GOLDEN, Colo. — August 2, 2022 — PharmaJet® , a biotech company that, with their innovative needle-free technology has developed a more effective way of administering drugs and biologics to accelerate research, commercialization and public health outcomes, announced that its partner, Scancell, will include needle-free delivery of their Phase 2 clinical study for treatment of patients with advanced melanoma.

Tags: , , ,

July 21, 2022


PharmaJet presents latest research showing Benefits of Needle-free at mRNA-Based Therapeutics Summit


GOLDEN, Colo. — July 19, 2022 — PharmaJet® , a company who has developed and commercialized a needle-free platform to more effectively administer drugs and biologics, today announced that they will present their latest research results at the mRNA-Based Therapeutics Summit on July 27, 2022. The presentation, entitled Advances in mRNA vaccines and therapeutics delivery with PharmaJet Needle-free Injection Systems, will be presented by Carmen Ledesma-Feliciano, DVM, PhD, DACLAM, Clinical Device Specialist at PharmaJet. This event, which takes place in Boston, will convene mRNA experts to highlight emerging tools and technologies that support the development of scalable and commercially viable mRNA-based therapeutics.

Tags: , , , , , , ,



PharmaJet Expands Manufacturing Capacity to meet Demand for its Needle-free Injection System


PharmaJet Expands Manufacturing Capacity to meet Demand for its Needle-free Injection SystemIt’s all about teamwork, collaboration, and QualityPharmaJet has expanded its manufacturing capacity to meet the increasing demand as our partners commercialize their vaccines and pharmaceutical products. Read more below about the extraordinary effort and commitment our Quality and Operations teams and our collaborators demonstrated...

Manufacturing


Our Blogs


Our Blogs Previous 1 … 5 6 7 … 13 NextWhy Delivery Matters for Pandemic ReadinessRecent crises have shown that pandemics don’t simply strain health systems—they disrupt entire societies. Supply chains falter under global demand. Regulatory processes slow when speed is most vital. Health systems run short on qualified vaccinators. And affordability barriers delay access...

July 8, 2022


Events


Events 2026 Oct 29-30 Partnership Opportunities in Drug Delivery Boston, Massachusetts Schedule a Meeting With Us

July 7, 2022


PharmaJet presents multiple partners’ data demonstrating superior immunogenicity with their Needle-free Systems at BIO International Convention


GOLDEN, Colo. — July 5, 2022—PharmaJet®, a biotech company that, with their innovative needle-free technology has developed a more effective way of administering drugs and biologics to accelerate research, commercialization and public health outcomes, today announced that their latest research results were presented at the BIO International Convention in June. The presentation, entitled Improved Vaccine and Therapeutic Performance…without the Jab, was presented by Paul LaBarre, MS, MBA, Vice President Global Business Development at PharmaJet, Inc.

Tags: , , , , , ,

June 28, 2022


PharmaJet Partner, Nykode Therapeutics, Announces Positive Interim Results in HPV+ Cervical Cancer Phase 2 Trial


GOLDEN, Colo. — June 21, 2022 — PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, announced that its partner, Nykode Therapeutics announced positive interim results from its phase 2 trial of their novel candidate, VB10.16, in combination with checkpoint inhibitor atezolizumab for treating ad-vanced cervical cancer. The DNA-based therapeutic cancer vaccine is delivered with the PharmaJet needle-free injection technology.

Tags: , , ,

June 14, 2022


The Lancet Publication Shows Benefits of PharmaJet Needle-free delivery for World’s First Commercialized Plasmid DNA COVID-19 Vaccine


GOLDEN, Colo. — June 7, 2022 — PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, today announced that the phase 3 clinical study sponsored by their partner, Zydus Lifesciences, has been published in The Lancet. The peer-reviewed article, entitled Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomized, double-blind, placebo-controlled study in India, features ZyCoV-D, the world’s first plasmid-DNA vaccine approved for use in humans, delivered exclusively by the PharmaJet Tropis® Intradermal Needle-free Injection System.

Tags: , , ,

June 3, 2022


PharmaJet partner, Institute for Molecular Medicine, launches clinical trial for the first in human Alzheimer’s DNA Vaccine


GOLDEN, Colo. — May 24, 2022 — PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, announced that its partner, the Institute for Molecular Medicine (IMM) was awarded a $12 Million grant from the National Institute on Aging (NIA) division of the National Institutes of Health (NIH). The grant supports clinical trials of their beta-amyloid vaccines based on DNA and recombinant protein for the prevention of Alzheimer’s disease (AD). A phase 1 clinical study in the U.S. is expected to begin in second quarter 2022 and the vaccine will be exclusively delivered by the PharmaJet Tropis® Needle-free Injection System.

Tags: , , ,

May 13, 2022


PharmaJet Announces Addition of Darin Zehrung as Chief Business Development Officer


GOLDEN, Colo. — May 10, 2022 — PharmaJet ®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, today announced that Darin Zehrung has joined the executive leadership team as Chief Business Development Officer. Mr. Zehrung is a global health business executive with over 25 years of technical, business and research leadership experience, most notably with PATH, the global nonprofit improving public health. In this role he will lead the development of new business for the Company, advancing strategic partnerships with global health agencies such as GAVI, WHO, UNICEF, and CEPI, and establishing partnerships with private/public companies in the global health market to advance commercial opportunities.

Tags: , , ,

May 5, 2022


PharmaJet presents partner data demonstrating superior immunogenicity with their Needle-free Systems at World Vaccine Congress


GOLDEN, Colo. — April 27, 2022 — PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, today announced that their latest research results were presented at the World Vaccine Congress on April 20.  The presentation, entitled Benefits of Vaccine and Therapeutics Delivery with PharmaJet’s Needle-free Injection Systems, was presented by Carmen Ledesma-Feliciano, DVM, PhD, DACLAM, Clinical Device Specialist at PharmaJet, Inc.

Tags: , , , , , ,

April 22, 2022


PharmaJet Launches New Interactive Website


GOLDEN, Colo. — April 13, 2022 — PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, today announced the launch of their new website aimed at expanding partner support with on-line tools for more rapid and efficient pharmaceutical development. Focusing on PharmaJet’s mission, “Enabling greater access to life-improving pharmaceuticals”, the new website provides a better user experience, highlighting the improved performance that can be achieved with needle-free delivery and providing existing and potential partners easy access to valuable information and resources to help them make informed decisions.

Tags: , ,

April 13, 2022


Video features PharmaJet Needle-free Polio Immunization Campaign


GOLDEN, Colo. — March 29, 2022 — PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, announced the release of a video highlighting the recent implementation of a polio vaccination campaign in Somalia.

Tags: ,

March 29, 2022


Thank You


Thank You Thank you for contacting us!  We will be in touch with you shortly.

March 15, 2022


Page 6 of 13